Persado and Emarsys Announce Strategic Partnership to Give Marketers Seamless, Data-Driven Creative and Campaign Automation, Driving a 37 Percent Uplift on Average in CTR for Happy Socks
Persado, the leader in using AI to generate the best-performing marketing creative harnessing the power of words, today announced a strategic partnership with Emarsys, the only marketing platform that knows your industry. The integration combines Persado’s revolutionary platform for generating data-driven creative at scale, with Emarsys’ unmatched turnkey marketing solutions that support profitable revenue growth through smarter acquisition.
Joint Persado and Emarsys customers will now be able to generate, test and serve their marketing campaigns in minutes –– a fraction of the time of a traditional setup. Through the partnership’s API, campaign results will seamlessly flow back into Persado, giving clients access to quantitative and qualitative analysis on the variables that impact performance.
Happy Socks, a leading international and fashion-forward brand, turned to Persado and Emarsys to differentiate themselves during the most competitive marketing day of the year, Black Friday. Together, the partners executed a successful campaign that drove strong results and helped Happy Socks successfully engage customers.
“This integration is incredibly exciting because both Persado’s and Emarsys’ technologies are critical for driving success. Emarsys gives us freedom to easily setup and test campaigns, and Persado helps us empower our messages by generating the perfect language to improve our content’s performance and relevancy,” said Marc Verschueren, Director of Online Marketing and Sales at Happy Socks. “Coming out of our recent Black Friday campaign, we saw an average open rate uplift of 21 percent, and an average click-through-rate uplift of 37 percent. These technologies helped us stand out by taking more risks and thinking outside the box, all without worrying about missing the mark.”
“Today’s CMOs are bombarded with solutions claiming to drive ROI, so identifying the technologies and offerings that provide real value has become increasingly difficult. Marketing teams need products that intelligently achieve results and close the gap between goals and outcomes,” said Assaf Baciu, Co-Founder & SVP of Product and Engineering, Persado. “Through this partnership, we are uniting automation with intelligence. Persado’s AI fully unlocks the power of words and gives marketers certainty in their creative so that they can make every customer interaction count. We are thrilled to work together to give marketers the confidence they deserve.”
“We know that poor attempts to tailor communications will turn customers off. Marketers therefore rely on smart technology to automate and personalize communications across channels, at scale and often in real-time,” said Dave Littlechild, Global Head of Partnerships & Alliances at Emarsys. “This partnership helps us bridge the technology adoption gap that stands between a marketer and his or her ability to profitably driving more revenue. We are excited and look forward to the future as partners.”
The integration of Persado within Emarsys is complete and available to clients now. For more information, visit persado.com and emarsys.com.
Persado is reinventing digital marketing creative by applying mathematical certainty to words, the foundational DNA of Marketing. By unlocking the power of words, companies win every digital marketing moment, experiencing dramatic new levels of brand engagement and revenue performance. CMOs from the world’s most valuable brands rely on Persado to generate in a dramatically new way to unlock the power of words and emotionally engage consumers, one by one, moment by moment at scale.
The Persado Message Machine uses sophisticated AI, data science, computational linguistics and machine learning to generate the perfect message for every campaign by leveraging the world’s most advanced marketing language knowledgebase of more than one million tagged and scored words and phrases. Marketers gain full visibility with quantifiable results and data-driven insights to identify the trends and emotional language that win every moment in the customer journey while ensuring the marketing message always reinforce brand voice.
For more information about Persado or to schedule a demo, please visit persado.com, and follow Persado on Twitter.
Emarsys is the largest independent marketing platform company in the world. The company provides actionable intelligence to enterprises targeting their consumers, combining machine learning and data science with true personalization and multichannel delivery to reach consumers most effectively, maximizing engagement and results. With more than 800 employees in 15 global office locations, Emarsys serves more than 2,300 clients in 140 countries. Every month, Emarsys sends over seven billion messages — helping consumers increase revenue and ROI. To learn more about Emarsys visit emarsys.com.
LaunchSquad for Persado
Natalie Homer, Global PR Manager for Emarsys
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 10:00:00 EEST | Tiedote
Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic
XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 21:20:00 EEST | Tiedote
On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 17:00:00 EEST | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo
Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 13:20:00 EEST | Tiedote
Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 08:00:00 EEST | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 04:00:00 EEST | Tiedote
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme